Donor stem cell transplant for relapsed T or NK lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests an allogeneic (donor) stem cell transplant for people with T-cell or NK-cell lymphomas that came back or did not respond to prior treatment. It may help by giving you new, healthy immune cells that can attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 19 and 65 years old
- You have a confirmed T-cell or NK-cell lymphoma, such as peripheral T-cell lymphoma, anaplastic large cell lymphoma, or NK/T-cell lymphoma
- Your lymphoma is back or not responding after previous chemotherapy (including any upfront transplant you already had)
- You have at least one measurable cancer spot seen on CT or PET/CT, and you improved to complete or partial response after short “salvage” chemotherapy
- You can get stem cells from a donor who matches you well (fully matched, or one “mismatch” from a sibling, or a matched unrelated/donor source)
- Your heart, kidney, liver, lung tests, and overall health are good enough for transplant (including ECOG 0–2 and Charlson score 3 or less)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs given before a donor stem cell transplant for people with NK/T-cell lymphoma. The goal is to see if this preconditioning helps the transplant work better.
This trial tests a combination of two chemotherapy drugs (pralatrexate and bendamustine) plus total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has come back or hasn't responded to treatment. The goal is to see if this approach can help destroy the lymphoma and allow the donor cells to take hold safely.
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
This trial tests a new treatment for patients whose acute myeloid leukemia (AML) has come back after a stem cell transplant. It uses immune cells from the original donor, combined with a low dose of a protein called IL-2, to try to fight the leukemia without causing severe side effects.
This early-phase study tests a combination treatment—chemo, immunotherapy, and a donor stem cell transplant—for certain aggressive NK/T-cell lymphomas. It may help patients who have advanced-stage disease by trying to improve long-term control of the cancer.
Hear when a new T-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.